x

Search for a networks

* (*) mandatory field

APL-A-005-02: Phase I - II clinical and pharmacokinetic study of Aplidin (APL) as a 3-hour intravenous infusion every 2 weeks, in children with refractory or relapsed malignant tumours and leukemia (coordination)

  • Type of network : Multinational clinical trials
  • Geographic coverage : European
  • Funding body(ies) : -
  • Sponsor : Pharma mar sa
  • Coordinator of multinational clinical trial

  • PHARMA MAR SA
  • Pharma Mar S.A.
  • PharmaMar S.A.
  • Avenida de los Reyes, 1. Polígono Industrial La Mina-Norte
  • 28770 COLMENAR VIEJO
  • SPAIN
  • More information
  • Phone  : 349 18 46 60 00
  • Fax  : 349 18 46 60 01
  • Website
  • Contact secretary  :
Last update: March 2011

Additional information

The documents contained in this web site are presented for information purposes only. The material is in no way intended to replace professional medical care by a qualified specialist and should not be used as a basis for diagnosis or treatment.